Oncology exam 1 SUMMARY (AB_1184); study: Gezondheid en Leven / Biomedical Sciences; VU Amsterdam
Samenvatting Oncology
Summary Oncology Molecular Biology of Cancer chapter 7-14
All for this textbook (19)
Written for
Vrije Universiteit Amsterdam (VU)
Biomedical Sciences
Oncology
All documents for this subject (41)
2
reviews
By: kallah2002 • 2 year ago
By: phebevanstraten • 3 year ago
Seller
Follow
biomedicalsciencesvu
Reviews received
Content preview
Chapter 14 Drug development of targeted therapy in oncology
Stages of drug development
1. Molecular target
2. Screen for inhibitor or activators
3. Drug formulation is optimization
4. Drug tested in pre-clinical studies
5. Clinical trials
a. Phase 0: drugs are tested during a short period (<7 days) for
metabolism, targeting and pharmacokinetics
b. Phase I: dose of the drug is escalated (verhogen) and new
combinations are tested. Primary endpoint: safety and tolerability
3+ 3 design: first 3 patients treated at dose K
- 0 patients experience dose-limiting toxicity K + 1
- 1 patient experience dose-limiting toxicity K
o In 1 of 6 experiences K+1
o In 2 or more of 6 experiences K-1
- 2 patients experience dose-limiting toxicity K-1
c. Phase II: one dose is tested in specific cancer type. Primary endpoint:
efficacy
d. Phase III: randomized studies in specific cancer types. Primary
endpoint: superiority or non-inferiority to standard treatment
e. Phase IV: one does is tested in specific cancer type. Primary endpoint
safety in larger group of patients
6. Drugs gets regulatory approval
Development of Gleevac (trademark) – first targeted therapy
o Drugs: imatinib inhibiting tyrosine phosphorylation
o Description: small-molecule inhibitor
o Target: BCR-ABL + Kit
o Cancer: chronic myeloid leukemia (CML) + Gastro-
intestinal stromacell tumor (GIST)
CML
CML has an abnormality is Philadelphia chromosome: result
from translocation of chromosomes 9 and 22 Generation of
the fusion protein BCR-ABL activate tyrosine kinase (ATP)
increase of leukemic cells
Treatment for CML: inhibitor of BCR-ABL tyrosine kinase
1. Molecular target: inhibitor of BCR-ABL tyrosine kinase
2. Screen for these
3. Drug formulation is optimization: potency and specificity was low by adding
different molecules it was able to optimize kinase inhibitory activity, specificity
and solubility resulting in the final compound imatinib
4. Drug tested in pre-clinical studies: tested in animal models
5. Clinical trials
a. Phase I: escalated the dose and monitor the side effects
b. Phase III: compare imatinib with standard treatment
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller biomedicalsciencesvu. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $3.21. You're not tied to anything after your purchase.
